GlobeNewswire Inc.··NaPliant Therapeutics' PLN-101095 Shows Promise in Hard-to-Treat Cancer Patients
Pliant Therapeutics presented Phase 1 data for PLN-101095 showing 89% average tumor reduction in ICI-refractory cancer patients, with Phase 1b expansion underway.
PLRXimmunotherapyPhase 1 trial